abstract：:Auto-SCT and Allo-SCT are procedures conventionally associated with intensive transfusion support. This dependence has historically prevented SCT in individuals with religious or personal objections to transfusion. More recently, a growing body of literature supports the feasibility of 'bloodless transplants': SCT wit...

journal_title：Bone marrow transplantation

authors： Sloan JM,Ballen K

更新日期：2008-05-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (ASCT) and its conditioning with chemoradiotherapy often results in liver toxicity, the most severe form being veno-occlusive liver disease (VOD). N-acetyl-L-cysteine (NAC), an antioxidant glutathione precursor, may provide protection from liver toxicity. Patients wit...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Hassan Z,Fransson K,Omazic B,Svahn BM,Karlsson H,Brune M,Hassan M,Mattsson J,Ringdén O

更新日期：2008-05-01 00:00:00

abstract：:Several high-dose therapy regimens are used for autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed and refractory Hodgkin's lymphoma (HL) with variable disease response. An intensified regimen of etoposide (VP-16) 2,400 mg/m(2), cyclophosphamide 7,200 mg/m(2) and carmustine (BCNU) 600 mg/m(2) ...

journal_title：Bone marrow transplantation

authors： Benekli M,Smiley SL,Younis T,Czuczman MS,Hernandez-Ilizaliturri F,Bambach B,Battiwalla M,Padmanabhan S,McCarthy PL Jr,Hahn T

更新日期：2008-04-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches. ...

journal_title：Bone marrow transplantation

authors： Shaw BE,Russell NH

更新日期：2008-03-01 00:00:00

abstract：:We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC)...

journal_title：Bone marrow transplantation

authors： Ueno NT,Rizzo JD,Demirer T,Cheng YC,Hegenbart U,Zhang MJ,Bregni M,Carella A,Blaise D,Bashey A,Bitran JD,Bolwell BJ,Elfenbein GJ,Fields KK,Freytes CO,Gale RP,Lazarus HM,Champlin RE,Stiff PJ,Niederwieser D

更新日期：2008-03-01 00:00:00

abstract：:Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

journal_title：Bone marrow transplantation

authors： Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

更新日期：2008-03-01 00:00:00

abstract：:We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group ...

journal_title：Bone marrow transplantation

authors： Wang Y,Ogawa Y,Dogru M,Kawai M,Tatematsu Y,Uchino M,Okada N,Igarashi A,Kujira A,Fujishima H,Okamoto S,Shimazaki J,Tsubota K

更新日期：2008-02-01 00:00:00

abstract：:Fludarabine is a purine analog that has demonstrated significant activity in B-cell malignancies, including CLL. Fludarabine also possesses an immunosuppressive effect and is being used to prevent GVHD in hematopoietic stem cell transplantation. However, the molecular mechanism by which fludarabine inhibits immunoreac...

journal_title：Bone marrow transplantation

authors： Nishioka C,Ikezoe T,Togitani K,Yokoyama A

更新日期：2008-02-01 00:00:00

abstract：:beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

journal_title：Bone marrow transplantation

authors： Bhatia M,Walters MC

更新日期：2008-01-01 00:00:00

abstract：:Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other immunosuppressive regimens is asso...

journal_title：Bone marrow transplantation

authors： Bashoura L,Gupta S,Jain A,Couriel DR,Komanduri KV,Eapen GA,Safdar A,Broglio KR,Adachi R,Dickey BF

更新日期：2008-01-01 00:00:00

abstract：:Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for example, radiotherapy in infants) or ineffective (for example, recurrent malignant tumors). With this...

journal_title：Bone marrow transplantation

authors： Marachelian A,Butturini A,Finlay J

更新日期：2008-01-01 00:00:00

abstract：:One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolate...

journal_title：Bone marrow transplantation

authors： Mehta J,Singhal S

更新日期：2007-12-01 00:00:00

abstract：:A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997-2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at 1-21 days after HSCT (median 13 d...

journal_title：Bone marrow transplantation

authors： Cheuk DK,Wang P,Lee TL,Chiang AK,Ha SY,Lau YL,Chan GC

更新日期：2007-11-01 00:00:00

abstract：:Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

journal_title：Bone marrow transplantation

authors： Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

更新日期：2007-11-01 00:00:00

abstract：:In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

journal_title：Bone marrow transplantation

authors： Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

更新日期：2007-11-01 00:00:00

abstract：:Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of ...

journal_title：Bone marrow transplantation

authors： Kalaycio M,Rybicki L,Pohlman B,Dean R,Sweetenham J,Andresen S,Sobecks R,Sekeres MA,Advani A,Brown S,Bolwell B

更新日期：2007-10-01 00:00:00

abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

更新日期：2007-10-01 00:00:00

abstract：:Peg-filgrastim is a form of G-CSF with a sustained duration of action due to self-limited clearance. We administered 6 mg peg-filgrastim to 18 autograft recipients on day +1 after transplantation for hematologic malignancies. Plasma samples were collected at baseline and during transplantation. Hematopoietic recovery ...

journal_title：Bone marrow transplantation

authors： Piccirillo N,De Matteis S,De Vita S,Laurenti L,Chiusolo P,Sorà F,Reddiconto G,d'Onofrio G,Leone G,Sica S

更新日期：2007-09-01 00:00:00

abstract：:Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

journal_title：Bone marrow transplantation

authors： Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

更新日期：2007-09-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some r...

journal_title：Bone marrow transplantation

authors： Smith SD,Bolwell BJ,Rybicki LA,Brown S,Dean R,Kalaycio M,Sobecks R,Andresen S,Hsi ED,Pohlman B,Sweetenham JW

更新日期：2007-08-01 00:00:00

abstract：:Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

journal_title：Bone marrow transplantation

authors： Johnson MD,Perfect JR

更新日期：2007-08-01 00:00:00

abstract：:To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

journal_title：Bone marrow transplantation

authors： Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

更新日期：2007-08-01 00:00:00

abstract：:HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

journal_title：Bone marrow transplantation

authors： Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

更新日期：2007-07-01 00:00:00

abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

journal_title：Bone marrow transplantation

authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

更新日期：2007-06-01 00:00:00

abstract：:Information regarding the chimeric status of hematopoietic stem cell transplantation (HSCT) recipients is of great significance when comparing different conditioning and prophylactic therapies. In recent years, short tandem repeats/variable number tandem repeats (STRs/VNTRs) have emerged as the best tool for chimerism...

journal_title：Bone marrow transplantation

authors： Talwar S,Khan F,Nityanand S,Agrawal S

更新日期：2007-05-01 00:00:00

abstract：:A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

journal_title：Bone marrow transplantation

authors： Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

更新日期：2007-04-01 00:00:00

abstract：:We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remi...

journal_title：Bone marrow transplantation

authors： Sanz MA,Labopin M,Gorin NC,de la Rubia J,Arcese W,Meloni G,Bacigalupo A,Alessandrino P,Carreras E,Iriondo A,Novitzky N,Jacobs P,Bandini G,Lo-Coco F,Frassoni F,Rocha V,Acute Leukemia Working Party (ALWP) of European Cooper

更新日期：2007-04-01 00:00:00

abstract：:Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related...

journal_title：Bone marrow transplantation

authors： Gori E,Arpinati M,Bonifazi F,Errico A,Mega A,Alberani F,Sabbi V,Costazza G,Leanza S,Borrelli C,Berni M,Feraut C,Polato E,Altieri MC,Pirola E,Loddo MC,Banfi M,Barzetti L,Calza S,Brignoli C,Bandini G,De Vivo A,B

更新日期：2007-03-01 00:00:00

abstract：:Human cytomegalovirus (CMV) is a major cause of death after transplantation. The frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during the first year after transplantation. Patients were divided into four groups based on donor/recipient serostatus: d+/r+ (n=17), d+/r- (n=7), d-/r+ (...

journal_title：Bone marrow transplantation

authors： Ganepola S,Gentilini C,Hilbers U,Lange T,Rieger K,Hofmann J,Maier M,Liebert UG,Niederwieser D,Engelmann E,Heilbronn R,Thiel E,Uharek L

更新日期：2007-03-01 00:00:00

abstract：:This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal se...

journal_title：Bone marrow transplantation

authors： Yoon KC,Jeong IY,Im SK,Park YG,Kim HJ,Choi J

更新日期：2007-02-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare subacute demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. In immunocompromised hosts, PML is caused by reactivation of a latent infection rather than de novo primary exposure. PML in the setting of hematopoiet...

journal_title：Bone marrow transplantation

authors： Kharfan-Dabaja MA,Ayala E,Greene J,Rojiani A,Murtagh FR,Anasetti C

更新日期：2007-01-01 00:00:00

abstract：:We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

journal_title：Bone marrow transplantation

authors： Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

更新日期：2006-11-01 00:00:00

abstract：:Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT). We observed a high incidence of hepatic veno-occlusive disease (VOD) in transplanted patients and explored the prevention of this complication by using ...

journal_title：Bone marrow transplantation

authors： Corbacioglu S,Hönig M,Lahr G,Stöhr S,Berry G,Friedrich W,Schulz AS

更新日期：2006-10-01 00:00:00

abstract：:Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were mea...

journal_title：Bone marrow transplantation

authors： Hendriks MP,Blijlevens NM,Schattenberg AV,Burger DM,Donnelly JP

更新日期：2006-10-01 00:00:00

abstract：:We conducted a prospective randomized clinical trial to assess the mobilizing efficacy of filgrastim, lenograstim and molgramostim following a disease-specific chemotherapy regimen. Mobilization consisted of high-dose cyclophosphamide in 45 cases (44%), and cisplatin/ifosfamide/etoposide or vinblastine in 22 (21%), fo...

journal_title：Bone marrow transplantation

authors： Kopf B,De Giorgi U,Vertogen B,Monti G,Molinari A,Turci D,Dazzi C,Leoni M,Tienghi A,Cariello A,Argnani M,Frassineti L,Scarpi E,Rosti G,Marangolo M

更新日期：2006-09-01 00:00:00

abstract：:The First International Symposium on Photopheresis in Hematopoietic Stem Cell Transplantation was held in Vienna, Austria with an educational grant from Therakos Inc. from 25 May to 27 May 2005. Three general issues were addressed: (1) pathophysiology of graft-versus-host disease (GvHD), (2) induction of immune tolera...

journal_title：Bone marrow transplantation

authors： Greinix HT,Socié G,Bacigalupo A,Holler E,Edinger MG,Apperley JF,Schwarz T,Ullrich SE,Albert ML,Knobler RM,Peritt D,Ferrara JL

更新日期：2006-08-01 00:00:00

abstract：:The natural history of multiple myeloma (MM) was revolutionized by the introduction of haematopoietic stem cell transplantation to the treatment armamentarium of this disease. Defined subgroups of MM patients (such as the elderly or dialysis-dependent) have required an individualized approach in order to minimize the ...

journal_title：Bone marrow transplantation

authors： Bahlis NJ,Lazarus HM

更新日期：2006-07-01 00:00:00

abstract：:The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4+ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients we...

journal_title：Bone marrow transplantation

authors： Kim DH,Sohn SK,Won DI,Lee NY,Suh JS,Lee KB

更新日期：2006-06-01 00:00:00

abstract：:Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

journal_title：Bone marrow transplantation

authors： Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

更新日期：2006-05-01 00:00:00